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Abstract
Whole-genome sequencing harbors unprecedented potential for characterization of individual and family genetic variation.
Here, we develop a novel synthetic human reference sequence that is ethnically concordant and use it for the analysis of
genomes from a nuclear family with history of familial thrombophilia. We demonstrate that the use of the major allele
reference sequence results in improved genotype accuracy for disease-associated variant loci. We infer recombination sites
to the lowest median resolution demonstrated to date (,1,000 base pairs). We use family inheritance state analysis to
control sequencing error and inform family-wide haplotype phasing, allowing quantification of genome-wide compound
heterozygosity. We develop a sequence-based methodology for Human Leukocyte Antigen typing that contributes to
disease risk prediction. Finally, we advance methods for analysis of disease and pharmacogenomic risk across the coding
and non-coding genome that incorporate phased variant data. We show these methods are capable of identifying
multigenic risk for inherited thrombophilia and informing the appropriate pharmacological therapy. These ethnicity-specific,
family-based approaches to interpretation of genetic variation are emblematic of the next generation of genetic risk
assessment using whole-genome sequencing.
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Introduction
Whole genome sequencing of related individuals provides a
window into human recombination as well as superior error
control and the ability to phase genomes assembled from high
throughput short read sequencing technologies. The interro-
gation of the entire euchromatic genome, as opposed to the
coding exome, provides superior sensitivity to recombination
events, allows for full interrogation of regulatory regions, and
comprehensive exploration of disease associated variant loci, of
which nearly 90% fall into non-protein-coding regions [1]. The
recent publication of low-coverage sequencing data from large
numbers of unrelated individuals offers a broad catalog of
genetic variation in three major population groups that is
complementary to deep sequencing of related individuals [2].
Recently, investigators used a family-sequencing approach to
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fine map recombination sites, and combined broad population
genetic variation data with phased family variant data to
identify putative compound heterozygous loci associated with
the autosomal recessive Miller syndrome [3]. We previously
developed and applied a methodology for interpretation of
genetic and environmental risk in a single subject using a
combination of traditional clinical assessment, whole genome
sequencing, and integration of genetic and environmental risk
factors [4]. The combination of these methods and resources
and their application to phased genetic variant data from family
based sequencing has the potential to provide unique insight
into topology of genetic variation, haplotype information, and
genetic risk.
One of the challenges to interpretation of massively parallel
whole genome sequence data is the assembly and variant calling of
sequence reads against the human reference genome. Although de
novo assembly of genome sequences from raw sequence reads
represents an alternative approach, computational limitations and
the large amount of mapping information encoded in relatively
invariant genomic regions make this an unattractive option
presently. The National Center for Biotechnology Information
(NCBI) human reference genome in current use [5] is derived
from DNA samples from a small number of anonymous donors
and therefore represents a small sampling of the broad array of
human genetic variation. Additionally, this reference sequence
contains both common and rare disease risk variants, including
rare susceptibility variants for acute lymphoblastic leukemia and
the Factor V Leiden allele associated with hereditary thrombo-
philia [6]. Thus, the use of the haploid NCBI reference for variant
identification using high throughput sequencing may complicate
detection of rare disease risk alleles. Furthermore, the detection of
alternate alleles in high-throughput sequence data may be affected
by preferential mapping of short reads containing the reference
base over those containing an alternate base [7]. The effects of
such biases on genotype accuracy at common variant loci remain
unclear.
Here we report the development of a novel, ethnically
concordant major allele reference sequence and the evaluation
of its use in variant detection and genotyping at disease risk loci.
Using this major allele reference sequence, we provide an
assessment of haplotype structure and phased genetic risk in a
family quartet with familial thrombophilia.
Results
Study subjects and genome sequence generation
Clinical characteristics of the study subjects and the heuristic
for the genome sequence generation and analysis are described
in Figure 1. Two first-degree family members, including the
father in the sequenced quartet, have a history of venous
thrombosis; notably, the sequenced father has a history of
recurrent venous thromboembolism despite systemic anticoag-
ulation. Both parents self-reported northern European ancestry.
We used the Illumina GAII sequencing platform to sequence
genomic DNA from peripheral blood monocytes from four
individuals in this nuclear family, providing 39.3x average
coverage of 92% of known chromosomal positions in all four
family members (Figure S1).
Development of ethnicity-specific major allele references
We developed three ethnicity specific major allele references
for European (European ancestry in Utah (CEU)), African
(Yoruba from Ibadan, Nigereia (YRI)), and East Asian (Han
Chinese from Beijing and Japanese from Tokyo (CHB/JPT))
HapMap population groups using estimated allele frequency data
at 7,917,426, 10,903,690, and 6,253,467 positions cataloged in
the 1000 genomes project. Though relatively insensitive for very
rare genetic variation, the low coverage pilot sequencing data
(which comprises the majority of population-specific variation
data) has a sensitivity for an alternative allele of .99% at allele
frequencies .10% and thus has high sensitivity for detecting the
major allele [2]. Substitution of the ethnicity-specific major allele
for the reference base resulted in single base substitutions at
1,543,755, 1,658,360, and 1,676,213 positions in the CEU, YRI,
and CHB/JPT populations, respectively (Figure 2A). There were
796,548 positions common to all three HapMap population
groups at which the major allele differed from the NCBI
reference base. Variation from the NCBI reference genomes was
relatively uniform across chromosomal locations with the
exception of loci in and near the Human Leukocyte Antigen
(HLA) loci on chromosome 6p21 (Figure 2C). Of variant
positions associated with disease in our manually curated
database of 16,400 genotype-disease phenotype associations,
4,339, 4,451, and 4,769 are represented in the NCBI reference
sequence by the minor allele in the CEU, YRI, and CHBJPT
populations, respectively (Figure 2B). There are 1,971 disease-
associated variant positions represented on the NCBI reference
sequence by the minor allele in all three population groups
(Figure 2B). Of these manually-curated disease-associated vari-
ants, 23 are represented on the NCBI reference sequence by
minor alleles with a frequencies of less than 5% in all three
population groups, and 18 are represented by minor alleles with
frequencies of less than 1% in at least one population group
(Table S1).
To test the alignment performance of the major allele reference
sequences, we performed alignments of one lane of sequence data
to chromosome 6, which demonstrated the greatest population-
specific divergence between the major allele in each HapMap
population and the NCBI reference, and chromosome 22 in the
NCBI and CEU major allele references (Table S2). These
analyses demonstrated that ,0.01% more reads mapped
uniquely to the major allele reference sequence than to the
NCBI reference sequence. We identified sequence variants in the
family quartet by comparison with the HG19 reference as well
Author Summary
An individual’s genetic profile plays an important role in
determining risk for disease and response to medical
therapy. The development of technologies that facilitate
rapid whole-genome sequencing will provide unprece-
dented power in the estimation of disease risk. Here we
develop methods to characterize genetic determinants of
disease risk and response to medical therapy in a nuclear
family of four, leveraging population genetic profiles from
recent large scale sequencing projects. We identify the
way in which genetic information flows through the family
to identify sequencing errors and inheritance patterns of
genes contributing to disease risk. In doing so we identify
genetic risk factors associated with an inherited predispo-
sition to blood clot formation and response to blood
thinning medications. We find that this aligns precisely
with the most significant disease to occur to date in the
family, namely pulmonary embolism, a blood clot in the
lung. These ethnicity-specific, family-based approaches to
interpretation of individual genetic profiles are emblematic
of the next generation of genetic risk assessment using
whole-genome sequencing.
Genetic Risk in a Family Quartet
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the CEU major allele reference we developed, resulting in single
nucleotide substitutions at an average distance of 699 base pairs
when compared with the NCBI reference and 809 base pairs
when compared with the CEU major allele reference. We also
identified 859,870 indels at an average inter-marker distance of
3.6 kbp.
Figure 1. Pedigree and genetic risk prediction workflow. A, Family pedigree with known medical history. The displayed ages represent the
age of death for deceased subjects or the age at the time of medical history collection (9/2010) for living family members. Arrows denote sequenced
family members. Abbreviations: AD, Alzheimer’s disease; CABG, coronary artery bypass graft surgery; CHF, congestive heart failure; CVA,
cerebrovascular accident; DM, diabetes mellitus; DVT, deep venous thrombosis; GERD, gastroesophageal reflux disease; HTN, hypertension; IDDM,
insulin-dependent diabetes mellitus; MI, myocardial infarction; SAB, spontaneous abortion; SCD, sudden cardiac death. B, Workflow for phased
genetic risk evaluation using whole genome sequencing.
doi:10.1371/journal.pgen.1002280.g001
Genetic Risk in a Family Quartet
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Figure 2. Development of major allele reference sequences. Allele frequencies from the low coverage whole genome sequencing pilot of the
1000 genomes data were used to estimate the major allele for each of the three main HapMap populations. The major allele was substituted for the
NCBI reference sequence 37.1 reference base at every position at which the reference base differed from the major allele, resulting in approximately
1.6 million single nucleotide substitutions in the reference sequence. A, Approximately half of these positions were shared between all three HapMap
population groups, with the YRI population containing the greatest number of major alleles differing from the NCBI reference sequence. B, Number
of disease-associated variants represented in the NCBI reference genome by the minor allele in each of the three HapMap populations. C, Number of
positions per Mbp at which the major allele differed from the reference base by chromosome and HapMap population.
doi:10.1371/journal.pgen.1002280.g002
Genetic Risk in a Family Quartet
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A major allele reference sequence reduces genotyping
error at variant loci associated with disease traits
Specific to the family quartet, of 16,400 manually-curated
single nucleotide polymorphisms associated with disease traits,
10,396 were variant in the family when called against the NCBI
reference genome, and 9,389 were variant in the family when
called against the major allele reference genome. The genotyping
error rate for these disease-associated variants, estimated by the
Mendelian inheritance error (MIE) rate per variant, was 38%
higher in the variants called by comparison with the NCBI
reference genome (5.8 per 10,000 variants) than in variants called
by comparison with the major allele reference genome (4.2 per
10,000 variants). There were 233 genotype calls at 130 disease-
associated variant positions that differed across the quartet
between the NCBI reference genome and the major allele
reference genome (summary for each genome is provided in
Table S3). Among these variants, 161/188 genotypes (85.6%) in
the major allele call set were concordant with genotypes from
orthogonal genotyping technology, whereas only 68/188 (36.2%)
in the NCBI call set were concordant with independent
genotyping.
Inheritance state analysis identifies .90% of sequencing
errors
Sequencing family quartets allows for precise identification of
meiotic crossover sites from boundaries between inheritance
states and superior error control [3]. We resolved contiguous
blocks of single nucleotide variants into one of four Mendelian
inheritance states or two error states. Using this methodology,
we identified 3.1% of variant positions as associated with error
prone regions (Figure 3A). Using a combination of these
methods and quality score calibration with orthogonal geno-
typing technology, we identified 94% of genotyping errors, with
the greatest reduction in error rate resulting from filtering of
variants in error prone regions (Figure 3B). We estimated a
final genotype error rate by three methods of between
5.2661027, estimated by the state consistency error rate in
identical-by-descent regions, and 2.161026, estimated by the
MIE rate per bp sequenced.
Prior population mutation rate estimates are biased
upwards by the reference sequence
After excluding variants in sequencing-error prone regions, we
identified 4,302,405 positions at which at least one family member
differed from the NCBI reference sequence and 3,733,299
positions at which at least one family member differed from the
CEU major allele reference sequence (Figure S2). With respect to
the NCBI reference sequence, this corresponds to an estimated
population mutation rate (Watterson’s h [8]) of 9.261024,
matching previous estimates [3]. However, in comparison with
the CEU major allele reference, we estimated a lower population
mutation rate of 7.861024, suggesting that previous estimates may
have been biased upwards by comparison with the NCBI
reference sequence.
Male and female recombinations occur with nearly equal
frequency in this family and approximately half occur in
hotspots
Boundaries between contiguous inheritance state blocks defined
55 maternal and 51 paternal recombination events across the
quartet at a median resolution of 963 base pairs. A parallel
heuristic analysis of recombination sites confirmed our observation
of nearly equal paternal and maternal recombination frequency
(Figure 3C). Fine scale recombination mapping and long range
phasing revealed that the mother has two haplotypes ([C, T] and
[T, T]) at SNPs rs3796619 and rs1670533 that are associated with
low recombination rates in females, while the father has one
haplotype associated with low recombination rate in males [T, C]
[9]. The father also has the common [C,T] haplotype which is
associated with high recombination rates in males when compared
with the other two observed haplotypes. We found that 25 of 51
paternal recombination windows (49%) and 27 of 55 maternal
recombination windows (49%, Figure 3) were in hotspots (defined
by maximum recombination rate of .10 cM/Mbp), while only
,4 (4.1%) would be expected by chance alone (p=2.0610273 for
hotspot enrichment according to Monte Carlo permutation). Both
parents carry 13 zinc finger repeats in the PRDM9 gene (Entrez
Gene ID 56979) and are homozygous for the rs2914276-A allele;
both of these loci have been previously associated with
recombination hotspot usage [10–13]. We used a combination
of per-trio phasing, inheritance state of adjacent variants, and
population linkage disequilibrium data to provide long range
phased haplotypes (Figure 3D).
Rare variant analysis identifies multi-genic risk for familial
thrombophilia
It has been estimated from population sequencing data that
apparently healthy individuals harbor between 50 and 100
putative loss of function variants in genes associated with
Mendelian diseases and traits [2]. Many of these variants are
of limited import, either because they result in subtle phenotypes
or have no biological effect. Thus, prioritization of putative loss
of function variants remains a significant challenge. We used a
combination of manually-curated rare-variant disease risk
association data, an internally-developed method for scoring
risk variants according to potential clinical impact, and existing
prediction algorithms [14,15] (Figure S3 and Table S4) to
provide genetic risk predictions for phased putative loss-of-
function variants for the family quartet (Table 1). To further
characterize the potential adverse effects of non-synonymous
single nucleotide variants (nsSNVs), we implemented a multiple
sequence alignment (MSA) of 46 mammalian genomes, de-
scribed further in Text S1, that is similar to that implemented in
the Genomic Evolutionary Rate Profiling score [16,17]. For
coding variants of unknown significance, the mammalian
evolutionary rate is proportional to the fraction of selectively
neutral alleles [18] and can therefore serve as a prior expectation
in determining the likelihood that an observed nsSNV is
deleterious.
Of 354,074 rare or novel variants compared with the CEU
major allele reference sequence, we identified 200 non-synony-
mous variants in coding regions, 1 nonsense variant, 1 single
nucleotide variant (SNV) in the conserved 39 splice acceptor
dinucleotides, and 27 novel frame-shifting indels in genes
associated with Mendelian diseases or traits. Consistent with our
prior observations and a conserved regulatory role for microRNAs
(miRNAs), we found no rare or novel SNVs in mature miRNA
sequence regions or miRNA target regions in 39 UTRs. There
were four compound heterozygous variants in disease-related
genes and three homozygous variants in disease-related genes
(Table S6). Five variants across the family quartet are associated
with Mendelian traits (Table 2). One variant in the gene F5
(Entrez Gene ID 2153), encoding the coagulation factor V, confers
activated protein C resistance and increased risk for thrombophilia
[19,20]. Another variant (the thermolabile C677T variant) in the
gene MTHFR (Entrez Gene ID 4524), encoding methylenetetra-
hydrofolate reductase, predisposes heterozygous carriers to hyper-
Genetic Risk in a Family Quartet
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homocysteinemia and may have a synergistic effect on risk for
recurrent venous thromboembolism [21,22]. Follow-up serological
analysis demonstrated the father’s serum homocysteine concen-
tration was 11.5 mmol/L (Table S11). We were able to exclude a
homozygous variant in F2 (Entrez Gene ID 2147), a gene known
to be associated with hereditary thrombophilia, based on its high
evolutionary rate in multiple sequence alignment (Table S5). It is
likely that these variants in F5 andMTHFR contribute digenic risk
for thrombophilia passed to the daughter but not son from the
father. This is consistent with the father’s clinical history of two
venous thromboemboli, the second of which occurred on systemic
anticoagulation. The daughter has a third variant inherited from
her mother, the Marburg I polymorphism, in the hyaluronan
binding protein 2 (HABP2, Entrez Gene ID 3026) gene known to
be associated with inherited thrombophilia, thus contributing to
multigenic risk for this trait [23–25]. Thus, our prediction pipeline
recapitulated multigenic risk for the only manifest phenotype,
recurrent thromboembolism, in the family quartet and provided a
basis for a rational prescription for preventive care for the
daughter.
Association between synonymous SNVs (sSNVs) and disease has
recently been described [26]. sSNVs may affect gene product
function in several ways, including codon usage bias, mRNA
decay rates, and splice site creation and/or disruption (Figure S4).
We developed and applied an algorithm (Text S1), for predicting
loss of function effects of 186 rare and novel sSNVs in Mendelian
disease associated genes based on change in mRNA stability, splice
site creation and loss, and codon usage bias. We found that one
Figure 3. Inheritance state analysis, error estimation, and phasing. A, A Hidden Markov Model (HMM) was used to infer one of four
Mendelian and two non-Mendelian inheritance states for each allele assortment at variant positions across the quartet. ‘‘MIE-rich’’ refers to
Mendelian-inheritance error (MIE) rich regions. ‘‘Compression’’ refers to genotype errors from heterozygous structural variation in the reference or
study subjects, manifest as a high proportion of uniformly heterozygous positions across the quartet. B, A combination of quality score calibration
using orthogonal genotyping technology and filtering SNVs in error prone regions (MIE-rich and compression regions) identified by the HMM
resulted in .90% reduction in the genotype error rate estimated by the MIE rate. C, Consistent with PRDM9 allelic status, approximately half of all
recombinations in each parent occurred in hotspots. The mother has two haplotypes in the gene RNF212 associated with low recombination rates,
while the father has one haplotype each associated with high and low recombination rates. Notation denotes base at [rs3796619, rs1670533]. D,
Variant phasing using pedigree, inheritance state, and population linkage disequilibrium data. Pedigree data were first used to phase informative
allele assortments in trios (top). The inheritance state of neighboring regions was used to phase positions in which all members of a mother-father-
child trio were heterozygous and the sibling was homozygous for the reference or non-reference allele (middle). For uniformly heterozygous
positions, we phased the non-reference allele using a maximum likelihood model to assign the non-reference allele to paternal or maternal
chromosomes based on population linkage disequilibrium with phased SNVs within 250 kbp (bottom). In all panels a corresponds to the reference
allele and b to the non-reference allele.
doi:10.1371/journal.pgen.1002280.g003
Genetic Risk in a Family Quartet
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sSNV in the gene ATP6V0A4 (Entrez Gene ID 50617) was
predicted to significantly reduce mRNA stability, quantified by the
change in free energy in comparison with the reference base at
that position (Figure S5). Further secondary structure prediction
demonstrated that this SNV likely disrupts a short region of self-
complementarity that forms a stable tetraloop (Figure S5) in the
resultant mRNA. Homozygosity for loss of function (largely
protein truncating) variants in this gene is associated with distal
renal tubular acidosis, characterized by metabolic acidosis,
potassium imbalance, urinary calcium insolubility, and distur-
bances in bone calcium physiology [27].
Common variant risk prediction identifies risk for obesity
and psoriasis
Results from Genome Wide Association Studies (GWAS)
provide a rich data source for assessment of common disease risk
in individuals. To provide a population risk framework for genetic
risk predictions for this family quartet, we first localized ancestral
origins based on principal components analysis of common single
nucleotide polymorphism (SNP) data in each parent and the
Population Reference Sample (POPRES) dataset [28] (Figure 4A).
This analysis demonstrated North/Northeastern and Western
European ancestral origins for maternal and paternal lineages,
respectively.
HLA groups are associated with several disease traits and are
known to modify other genotype - disease trait associations [29–
31]. We used long-range phased haplotypes and an iterative search
(described in full in Text S1) for the nearest HLA tag haplotype
[32] to provide HLA types for each individual prior to
downstream risk prediction (Figure 4B and 4C). We then
calculated composite likelihood ratios (LR) for 28 common
diseases for 174 ethnically-concordant HapMap CEU individuals,
Table 1. Putative loss of function variants across the family quartet.
All variants All rare/novel
Rare/novel and OMIM-disease
associated gene
Variant type
HG19 reference
(n =4302405)
CEU reference
(n =3733299)
HG19 reference
(n=351555)
CEU reference
(n =354074) HG19 reference CEU reference
Coding-missense 9468 7982 1276 1276 203 200
Coding-nonsense 52 50 13 13 1 1
Coding-synonyn 11663 9928 1061 1059 186 186
Intronic 1303341 1128283 116276 115397 19544 19766
Splice-59 156 147 16 16 0 0
Splice-39 98 96 9 9 1 1
UTR-59 40142 37794 3637 3619 510 516
UTR-39 61826 59396 5989 5953 848 857
miRNA target 0 0 0 0 0 0
Pri-miRNA 2 2 1 1 0 0
Mature miRNA 0 0 0 0 0 0
Coding indels 1519 1476 432 412 73 71
Coding frameshift indels 440 418 273 253 29 27
Abbreviations: CEU reference, variant calls against CEU major allele reference; HG19 reference, variant calls against NCBI reference sequence 37.1; miRNA, micro RNA; Pri-
miRNA, primary microRNA transcript; OMIM, Online Mendelian Inheritance In Man database; UTR, un-translated region.
doi:10.1371/journal.pgen.1002280.t001
Table 2. Rare variants with known clinical associations.
Chromosome Gene rsid
Affected
family
members Disease Inheritance
Onset-
earliest
Onset-
median Severity Actionability
Lifetime
risk
Variant
pathogenicity
12 VWF rs61750615 M, S, D Von Willebrand
disease
Incomplete
dominant
1 1 5 5 variable 7
10 HABP2 rs7080536 M, S, D Carotid stenosis,
thrombophilia
AD 4 4 1 5 variable 7
19 SLC7A9 rs79389353 M, D Cysteinuria –
kidney stones
AR 1 1 3 5 7 7
1 F5 rs6025 F, D Thrombophilia Incomplete
dominant
4 4 4 5 2 7
1 MTHFR rs1801133 F, D Hyperhomocystein-
emia
AR 1 1 1 6 2 7
Key: Father, mother, son, daughter = F, M, S, D. Abbreviations: AD, autosomal dominant; AR, autosomal recessive. Variants were scored according to disease phenotype
features and variant pathogenicty as outlined in Table S4.
doi:10.1371/journal.pgen.1002280.t002
Genetic Risk in a Family Quartet
PLoS Genetics | www.plosgenetics.org 7 September 2011 | Volume 7 | Issue 9 | e1002280
and provided percentile scores for each study subject’s composite
LR for each disease studied (Figure 5A). All four family members
were at high risk for psoriasis, with the mother and daughter at
highest risk (98th and 79th percentiles, respectively). We also found
that both parents were predisposed to obesity, while both children
had low genetic risk for obesity. Discordant risks for common
disease between parents and at least one child were also seen for
esophagitis and Alzheimer’s disease. Phased variant data were
further used to provide estimates of parental contribution to
disease risk in each child according to parental risk haplotypes
(Figure 5B).
Pharmacogenomic variant annotation informs
thrombophilia therapeutics
We used the Pharmacogenomics Knowledge Base (PharmGKB,
http://www.pharmgkb.org/) to evaluate associations between
phased variants and 141 drugs (Tables S8, S9, S10). In light of
the family history of venous thrombosis and the father’s use of the
anticoagulant warfarin, we focused particularly on relationships
between SNPs and anticoagulant and antiplatelet agents. All
family members are homozygous for the most common CYP2C9
allele (CYP2C9*1, Table 3) associated with normal warfarin
pharmacokinetics, and heterozygous for the allele at VKORC1-
1639 (rs9923231) associated with therapeutic prolongation of the
international normalized ratio at low doses of warfarin. We used
this variant data and clinical data to predict the father’s exact
empirically-determined dose of warfarin (5 mg) using the Inter-
national Warfarin Pharmacogenetics Consortium dosing algo-
rithm [33].
We also found that the mother and daughter are both
homozygous for an ultra-rapid metabolism allele at CYP2C19
(Entrez Gene ID 1557), which encodes a key metabolizer of the
pro-drug clopidogrel, an antiplatelet agent used in the prevention
and therapy of cardiovascular disease. Because the metabolic
activity of CYP2C19 is directly correlated with the antiplatelet
activity of clopidogrel, there is a higher bleeding risk associated
with clopidogrel use in the mother and daughter. This finding has
significant implications for the daughter, who has multigenic risk
for thrombophilia and may require anticoagulant therapy should
she develop thrombosis; concomitant use of clopidogrel in this
setting may contribute further to bleeding risk associated with
systemic anticoagulation. Full details of pharmacogenetic variants
in other key metabolic enzymes and associated pharmacokinetic
and pharmacodynamic profiles are displayed in Table 4.
Discussion
Here we describe phased genetic risk assessment in a family
quartet using whole genome sequencing and an ethnicity-specific
Figure 4. Ancestry and immunogenotyping using phased variant data. A, Ancestry analysis of maternal and paternal origins based on
principle components analysis of SNP genotypes intersected with the Population Reference Sample dataset. B, The HMM identified a recombination
spanning the HLA–B locus and facilitated resolution of haplotype phase at HLA loci. Contig colors in the lower panel correspond to the inheritance
state as depicted in Figure 3A. C, Common HLA types for family quartet based on phased sequence data.
doi:10.1371/journal.pgen.1002280.g004
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major allele reference. In doing so we present several novel
findings: the development and application of ethnicity-specific
major allele reference sequences; the definition of meiotic
crossover sites to a median resolution of ,1000 base pairs; the
development of a computational algorithm to achieve genome-
wide long-range haplotype phasing; the application of this phasing
to HLA typing and clinical interpretation of genomes from a
family quartet using internally developed databases of all publicly
accessible genotype-phenotype association data; the demonstration
and quantification of discordance of inherited disease risk within a
nuclear family; and the successful prediction of the only manifest
disease phenotype in this family.
At ,1.6 million genomic positions, we found that the NCBI
reference sequence is represented by the minor allele in each of the
three HapMap populations, and over 4,000 of these variant loci
are associated with disease traits. Despite only a small difference in
the number of mapped reads between the major allele and NCBI
reference sequences, we demonstrated that the use of a major
allele reference reduces genotyping error at common disease-
associated variant loci by ,40%. Accordingly, among genotypes
at 130 disease-associated variant loci that differ between the major
allele reference and NCBI reference call sets, 85% of genotype
calls made against the major allele reference were confirmed by
orthogonal genotyping, whereas only 36% of calls made against
the NCBI reference genome were concordant with orthogonal
genotyping. These results suggest that there is genotyping bias
introduced by the use of a non-major allele at common variant
positions. This issue, which may be compounded by read-mapping
reference biases [7], may be of particular importance in lower
coverage depth sequencing projects, in which fewer sequence
reads are used to generate genotype likelihoods for variant loci.
Additionally, rare variants associated with larger disease risk,
including the rare variant in F5 associated with hereditary
thrombophilia in this family, are represented by the minor allele
on the haploid reference sequence at 23 positions. These estimates
are only for curated disease associations in the published literature;
the true number of rare disease risk alleles represented on the
human reference genome is likely higher. The use of this reference
sequence for whole genome sequence variant identification will
not result in variant calls at these positions if the subjects being
sequenced are homozygous for the risk allele. Using the major
allele reference sequence and genome sequence variation data
from a family quartet, we also provide new estimates for the
population mutation rate that illustrate the upward bias in prior
estimates that were derived via comparison with the NCBI human
reference genome.
The incorporation of variant phase information into genetic risk
prediction for common disease traits has several important
advantages. HLA types are associated with several disease traits
[29,30,34], contribute a major fraction of disease risk in
autoimmune diseases [31], and are major factors in determining
solid organ and tissue transplant compatibility. Classical methods
for HLA typing are expensive and time consuming. Human
leukocyte antigen (HLA) group typing from high-throughput short
read sequence data has previously been challenging due to the
high recombination frequency on chromosome 6 that complicates
phasing, as well as the extreme genetic diversity in the HLA loci.
Our approach that incorporates fine-mapping of recombination
events with long-range phasing from polymorphic markers specific
to the ethnic background of the sequenced family (i.e., variants
called against the CEU major allele reference) simplifies the task of
identifying tag haplotypes from high-throughput sequence data.
Furthermore, several common SNPs have been associated with
disease risk, most notably diabetes mellitus 2, in a sex specific
manner, such that maternal origin confers direct association with
risk of disease and paternal origin confers indirect association with
disease risk [35]. Our methods for determining parental origin of
risk alleles allows for precise risk assessment utilizing this
information as a prior, in contrast to un-phased genotype data.
Lastly, there is recent evidence that genetic risk scores based on
common variants can provide disease risk estimates that are
independent of family history [36]. Our phased risk estimates
complement these findings by providing, for the first time, a fine
map of the origins of discordant risks for common disease between
generations in a nuclear family, demonstrating discordant
parental-child disease risks for three common disease traits. Such
methods serve to underline the additional power provided by
sequencing over family history alone in providing more precise
estimates of the inherited risk for individuals.
Family quartet sequencing allowed us to provide a fine map of
meiotic crossover sites to sub-kb resolution, and we found that
meiotic crossovers happen with nearly equal frequency in male
and female parents in this family quartet. This is in contrast to
previous observations in a family quartet and in mice that
recombinations occur with greater frequency in females than in
males [3,37,38]. Recent estimates of human sex-specific recom-
bination rates have, however, demonstrated significant variation in
recombination number, particularly in females [13,39–41]. Two
SNPs (rs3796619 and rs1670533), separated by 17 kb in the gene
RNF212 (Entrez Gene ID 285498), form a haplotype that is
significantly associated with genome wide recombination rate in a
sex-specific manner, such that the haplotype associated with the
highest recombination rate in males is associated with a low female
recombination rate. Notably, the RNF212 haplotypes revealed by
long range phasing in this quartet are associated with lower than
average female and average male recombination rates [9]. These
haplotype combinations likely contribute to below average
recombination rate in the mother and average recombination
rate in the father, potentially explaining our observations.
In this family quartet we observed that approximately half of
recombinations occurred in previously identified hotspots. Hotspot
usage in humans is variable, and is largely associated with allelic
status at several loci in the vicinity of PRDM9 [10–13]. The
heritability for hotspot use explained by this locus is among the
highest of all described quantitative trait loci and is determined by
both single nucleotide substitutions in and near PRDM9 and the
number of zinc finger a-helices in exon 12 of the gene [13]. The
use of whole genome sequencing allows for fine mapping of these
Figure 5. Common variant risk prediction. A, Common variant risk prediction for 28 disease states for each of the family members (f, father; m,
mother; s, son; d, daughter) and 174 ethnicity-matched HapMap subjects. The x-axis in each plot represents the log10(likelihood ratio) for each
disease according to allelic distribution of SNPs identified in the literature as significantly associated with disease by 2 or more studies including 2000
or more total subjects. B, Upper left: pre (base) and post (bar end) estimates of disease risk for the father according to common variant risk prediction,
derived from the pre-probability of disease multiplied by the composite likelihood ratio from all SNPs meeting the criteria described above. Upper
right: Composite likelihood ratio estimates for disease risk according to common genetic variation. Blue bars represent paternal estimate, pink bars
represent maternal estimate, red points represent the estimate for the daughter, and blue points represent the estimate for the son. Lower panels:
parental haplotype contribution to disease risk for each child (points) for the daughter (lower left) and son (lower right). Blue shading represents
paternal haplotype risk allele contribution and pink shading represents maternal haplotype risk allele contribution.
doi:10.1371/journal.pgen.1002280.g005
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sites and investigation of the relationship between PRDM9
haplotypes and hotspot usage. Of the SNPs near PRDM9,
rs2914276 is most significantly associated with hotspot usage
heritability. In this quartet both parents are homozygous for the
rs2914276-A allele that is associated with high hotspot usage as
well as the number of zinc finger repeats in PRDM9 [13].
We leveraged the power of sequencing nuclear families for
identification of .90% of sequencing errors in the quartet,
providing unprecedented accuracy of sequence information used
for genetic risk interpretation and identification of compound
heterozygous and multigenic disease risk. This approach, first
applied to a family quartet in which two family members had
Miller syndrome and ciliary dyskinesia [3], was extended into a
tool for phasing genetic variants. We also applied algorithms for
multiple sequence alignment for novel and rare nonsynonymous
variant risk prediction, and functional prediction for the effects of
synonymous SNPs. In doing so we identified multigenic risk for
thrombophilia in the father and daughter, consistent with a history
of recurrent venous thromboembolism in the father despite
systemic anticoagulation. Notably, because the haploid human
reference genome contains the Factor V Leiden mutation, if any
family member had been homozygous for the Factor V Leiden
mutation, single genome analysis using the NCBI reference
sequence would not have identified this variant. This multigenic
risk for thrombophilia is more consistent with the father’s clinical
history of recurrent thromboembolism on systemic anticoagulation
than monogenic risk conferred by heterozygous factor V Leiden
alone [42]. Furthermore, multigenic risk for thrombophilia
identified in the daughter prior to first venous thrombosis has
significant clinical implications in terms of risk mitigation.
Many challenges to interpretation of whole genome sequencing
remain, both scientific and ethical [43,44]. Sequencing error,
reference sequence bias, lack of accurate information regarding
haplotype phase, and lack of variant level annotation are several
scientific challenges. The ethical challenges include privacy and
confidentiality concerns, and legal, social, and insurance ramifi-
cations associated with acquiring and divulging comprehensive
genetic information to research subjects or the general population.
This information may reveal unanticipated risk for inherited
disease traits that in some cases is based on incomplete or
incorrectly annotated genotype-phenotype association data [45].
Whole genome re-sequencing will also identify new variants of
unknown significant in genes associated with disease traits,
potentially triggering expensive secondary testing [46]. Further-
more, though there is evidence that divulging genetic disease risk
to unselected populations is not associated with short term
psychological risk or decrement in quality of life metrics in a
research setting [47,48], it is not clear that the current genetic
counseling workforce will have the capacity to deliver genetic data
and counsel individuals if whole genome re-sequencing becomes
widely available to the general population [43].
As technological advances lower the financial costs and time
associated with generating whole genome sequence data, our
ability to appropriately interpret these data must advance in step.
The ethnicity-specific, family-based approaches to interpretation
of genetic variation presented here are emblematic of the next
generation of genetic risk assessment using whole genome
sequencing.
Materials and Methods
Ethics statement
The study was approved by the Stanford University Institutional
Review Board and all study subjects attended genetic counseling
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and provided informed written consent (or assent, in the case of
the children). This consent process occurred at two points in time:
before the sequencing was performed (overseen by Illumina, Inc.,
and conducted with a clinical geneticist) and before this clinical
interpretation was performed (conducted with a genetic counselor,
a research assistant, and a physician). Pedigree and genotyping
results were discussed in a genetic counseling session in the context
of information that may be obtained in clinical interpretation of
genome sequence data and the personal and family risks and
benefits that may arise in obtaining this information [43].
DNA sequence generation
Genomic DNA was extracted from peripheral blood from the
study subjects and sequenced using reversible terminator massively
parallel sequencing on the GA II instrument at Illumina, Inc (San
Diego, CA). Seventy-five base pair paired-end reads were mapped
to the NCBI human reference genome 37.1 (HG19) using BWA
software version 0.5.8a [49] with local realignment around known
indels performed by the Genome Analyis Tool Kit (GATK) [50].
A total of 5.98 billion sequence reads mapped uniquely to the
reference sequence across the quartet, resulting in 448 gigabases of
sequence data. Variant calling was performed using SAMtools
multi-sample pileup and BCFtools by comparison with HG19 and
the CEU major allele reference sequence. Major allele reference
sequences for the CEU, YRI, and CHB/JPT populations are
available at http://datadryad.org/.
Inheritance state determination and recombination
mapping
We built on the inheritance state analysis algorithm developed
by Roach, et al [3], to resolve contiguous blocks of SNVs into one
of four Mendelian inheritance states using a Hidden Markov
Model: paternal identical, in which each child receives the same
allele from the father but different alleles from the mother;
maternal identical, in which each child receives the same allele
from the mother but different alleles from the father; identical; and
nonidentical. Two additional non-Mendelian inheritance states
were modeled (compression and Mendelian inheritance error
(MIE) rich, described in Text S1 [3]). The modeling of two
additional error states allowed for identification of error-prone
regions that are difficult to sequence or properly map and
genotype. After excluding error prone regions that are potential
sources of spurious recombination site inferences, we re-analyzed
the variant allele assortments using only four Mendelian
inheritance states, identifying meiotic crossover windows as
intervals between SNVs defining the end and start, respectively,
of contiguous inheritance state blocks.
Phasing
We applied a combination of per-trio pedigree information,
inheritance state information, and population linkage disequilib-
rium data, described in full in Text S1, to provide long-range
phasing of each of the four family members (Figure 3D). Briefly,
we resolved phase of heterozygous variants in the children by: 1)
the inheritance state of the surrounding variants in contiguous
inheritance blocks (for variant positions at which each of three
individuals in a father-mother-child trio was heterozygous for a
non-reference allele and the sibling was homozygous for the
reference or non-reference allele); 2) maximization of aggregate r2
from pair-wise pre-computed population linkage disequilibrium
data from the SNP Annotation and Proxy Search (SNAP) database
[51]. Phasing was performed for each adult in contigs according to
passage of allele contigs to one, both, or neither of the children.
Immunogenotyping
We used an iterative, leave-one-out heuristic search (Text S1)
for the nearest tag haplotype for common HLA types [32] using
phased variant data, assigning an HLA type to each chromosome
for each study subject based on this nearest tag haplotype.
Rare variant prioritization
We used a combination of prediction algorithms based on
characteristics of amino acid change and predicted protein
structural and functional changes (SIFT, Polyphen2) [14,15],
and a novel MSA of 46 mammalian species, in which we
computed the evolutionary rate and time span at each genomic
position according to the method of Fitch [52], to provide genetic
risk predictions about non-synonymous coding variants in
Mendelian-disease associated genes. These variants were further
manually annotated according to disease phenotype features and
variant pathogenicity as described in Table S4. Methods for
functional prediction of codon usage bias, splice site disruption,
and mRNA stability for synonymous coding variants, and
annotation of variants in important non-coding regions are
described in Text S1.
Common variant risk prediction
We have developed a manually curated database of greater than
4000 publications investigating associations between 35,997 SNPs
and 1,194 diseases or traits. We applied a combinatorial approach
for point estimation of likelihood ratios of disease-SNP association,
and generated composite likelihood ratios for groups of SNPs and
associated diseases as described previously [4] from phased genetic
variant data (described in full in the Text S1). In this analysis we
included disease-SNP associations replicated in greater than 2
genome wide association studies with a total sample size of greater
than 2000 individuals and only SNPs genotyped in the HapMap
CEU population to provide a population-risk framework for
interpreting composite likelihood ratios.
Pharmacogenomics
We compiled 432 clinical annotations between 298 SNPs and
drugs (Pharmacogenomics Knowledge Base, PharmGKB, http://
www.pharmgkb.org/). For all family members in the quartet we
evaluated associations between 248 phased SNPs, including 147
heterozygous loci, and 141 drugs (example annotation in Table
S7, variant summary annotations in Tables S8, S9, S10). A full
description of pharmacogenomic methods is found in Text S1.
Supporting Information
Figure S1 Genotype coverage in quartet subjects. Paired end
short reads were mapped to NCBI reference genome 37.1 as
described in Text S1. A, Percentage of total chromosome length
(including positions not covered by the reference sequence)
successfully genotyped in all four individuals in the family quartet.
Chromosome 23 = X chromosome, chromosome 24 = Y
chromosome. B, Haploid depth of coverage by chromosome and
individual at each successfully genotyped position. PG20 =
mother, PG21 = father, PG22 = son, PG23 = daughter.
(TIF)
Figure S2 Variant types and error rate estimates for variants
against NCBI reference 37.1 and CEU major allele reference.
After short read mapping and local realignment, variants were
called against the NCBI reference genome 37.1 and the CEU
major allele reference. We first filtered likely spurious variant calls
by mapping quality, read depth and genotyping quality. The
Genetic Risk in a Family Quartet
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inheritance state for all allele assortments was determined by
HMM and error prone regions (compression regions and
Mendelian inheritance error rich (MIE)-rich regions, which
represent likely sequencing errors) were identified and excluded.
A, We identified 606,757 fewer variants when compared the CEU
major allele reference than the NCBI reference genome 37.1
(HG19 reference). B,C, Approximately 8% and 9% of variants
called against the HG19 reference (B) and CEU major allele
reference (C) were rare (allele frequency ,5%) or novel (not found
in dbSNP or 1000 genomes pilot project data), respectively.
(TIF)
Figure S3 Search heuristic for rare and novel variants. We first
identified rare (allele frequency ,5%) and novel variants (not
found in dbSNP 132 or the august 2010 release of the 1000
genomes pilot data). We used the CCDS collection of coding
sequences to assign rare and novel variants to coding and
noncoding categories and annotated putative rare and novel loss
of function variants in coding and noncoding regions of genes
known to be associated with Mendelian diseases as defined by the
Online Mendelian Inheritance in Man database. This list of
variants was manually curated for association with known clinical
syndromes and variant pathogenicity and phenotype information
were scored as in Table S4.
(TIF)
Figure S4 Synonymous variant risk prediction. Three models
for the association between a synonymous SNVs and gene
function. A, Shifts in signal to noise ratios between energies of a
window of nucleotides that surround the SNV locus. The random
background model is generated as sequences that have identical
nucleotide composition except for a small interval that contains the
SNV locus, thus measuring the contribution of the reference and
polymorphic nucleotide to mRNA free energy, which is used as a
proxy of mRNA stability. B, Codon usage frequencies correlate
with ribosome latency and have been shown to affect, sometimes
dramatically, protein elongation dynamics. Codons are clustered
based on their position and usage frequencies, in both the
reference and SNV-containing transcript. Changes in cluster
centroids are given as a measure of local influences of codon
frequency changes to global codon usage structure. C, Splicing site
generation or disruption is measured as the change in predicted
odds ratio of a maximum entropy splicing model. All synonymous
SNVs were analyzed using these three criteria.
(TIF)
Figure S5 Synonymous SNV prediction identifies a putative loss
of function variant in ATP6V0A4. A, A Z score method for
predicting free energy change conferred by synonymous single
nucleotide variants identified loci in the coding region of
ATP6V0A4 associated with a significant change in mRNA free
energy. B, Predicted change in mRNA secondary structure by
C.T transition at rs74921348.
(TIF)
Table S1 Very rare (minor allele frequency ,1%) disease risk
alleles in the NCBI reference genome.
(DOC)
Table S2 BWA alignment efficiency using HG19 and the CEU
major allele reference genomes.
(DOC)
Table S3 Genotype changes for disease-associated variants using
a major allele reference sequence.
(DOC)
Table S4 Prioritization scheme for rare and novel single
nucleotide variants.
(DOC)
Table S5 Variants of potential significance in OMIM-curated
disease associated genes.
(DOC)
Table S6 Compound heterozygous and homozygous variants in
Mendelian disease associated genes.
(DOC)
Table S7 Example pharmacogenomics annotation.
(DOC)
Table S8 Variants associated with drug efficacy.
(DOC)
Table S9 Variants associated with adverse drug response.
(DOC)
Table S10 Variants associated with drug dosing.
(DOC)
Table S11 Laboratory assessment of the father.
(DOC)
Text S1 Supplementary materials and methods.
(DOC)
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